k 2022

Modelling of a rare mutation in the GALNT3 gene found in patient with teeth and bone defects using genetically engineered mice

KŘIVÁNEK, Jan, Marcel SCHÜLLER, Zuzana MARINČÁK VRANKOVÁ, Hana PÁLOVÁ, Ondřej SLABÝ et. al.

Základní údaje

Originální název

Modelling of a rare mutation in the GALNT3 gene found in patient with teeth and bone defects using genetically engineered mice

Autoři

KŘIVÁNEK, Jan (203 Česká republika), Marcel SCHÜLLER (203 Česká republika), Zuzana MARINČÁK VRANKOVÁ (703 Slovensko), Hana PÁLOVÁ (203 Česká republika), Ondřej SLABÝ (203 Česká republika), Radka CHALOUPKOVÁ (203 Česká republika), Petr NICKL (203 Česká republika), Petr KAŠPÁREK (203 Česká republika), Jan PROCHÁZKA (203 Česká republika), Radislav SEDLÁČEK (203 Česká republika) a Petra BOŘILOVÁ LINHARTOVÁ (203 Česká republika, garant, domácí)

Vydání

4th CPP Phenogenomics conference 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14310/22:00126786

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

gene;mutation

Anotace

V originále

Treatment of rare inherited diseases remains to be a challenging task. The young female patient was diagnosed with chronic recurrent multifocal osteomyelitis in childhood. During an early puberty, a panoramic X-ray of the jaws revealed numerous defects in the anatomy of the teeth, which included significant root shortening. In addition, her blood tests repeatedly showed abnormalities in phosphorus and vitamin D levels. However, no clear association was found to link the diagnoses. To identify the possible causative agent of these diseases, whole-exome sequencing of her DNA was recently performed. The patient was found to be a carrier of an extremely rare allele of the gene for polypeptide N-Acetylgalactosaminyltransferase 3 (GALNT3) as a recessive homozygote. Mutation in this gene was in a few clinical case studies associated with hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome. Modelling of the protein structure showed that the identified point mutation in this conserved sequence causes conformational changes in the protein with a presumed change in its function. In order to study the identified inherited disease, a genetically modified mouse model carrying the same point mutation was created. Studying this mouse model will not only provide the opportunity to explore all phenotypic manifestations but more importantly, to test new therapies.

Návaznosti

EF17_043/0009632, projekt VaV
Název: CETOCOEN Excellence
LM2018121, projekt VaV
Název: Výzkumná infrastruktura RECETOX (Akronym: RECETOX RI)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, RECETOX RI